CDMO Catalent has refuted claims that US rollout of the recently approved J&J vaccine has been slowed down by problems at its fill-finish facilities. Shortly after the US Food and Drug Administration (FDA) approved Johnson & Johnson’s single-shot  vaccine making it the third authorized COVID vaccine  in the US, the Financial Times reported that Catalent is suffering production problems that “have contributed to the US government being set to receive millions fewer doses than it expected this month.” The British…

South Korean firm Alteogen has partnered with CDMO MilliporeSigma to develop and produce biotherapeutics and monoclonal antibody drugs. The collaboration will see MilliporeSigma (the life sciences business of Germany’s Merck KGaA) provide Alteogen with late-stage manufacturing services which includes developing and producing recombinant biologics for clinical evaluation. “This agreement supports large-volume subcutaneous administration of biologics that would otherwise be administered as an IV infusion,” said head of Process Solutions at Merck, Andrew Bulpin. “This advances Merck’s strategy of providing breakthrough,…